Bank of New York Mellon Corp Trims Stock Position in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)

Bank of New York Mellon Corp decreased its stake in shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDAFree Report) by 52.2% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 249,569 shares of the biopharmaceutical company’s stock after selling 272,987 shares during the period. Bank of New York Mellon Corp’s holdings in Vanda Pharmaceuticals were worth $1,078,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in VNDA. JPMorgan Chase & Co. increased its position in shares of Vanda Pharmaceuticals by 4.8% in the first quarter. JPMorgan Chase & Co. now owns 363,768 shares of the biopharmaceutical company’s stock worth $4,114,000 after acquiring an additional 16,716 shares in the last quarter. MetLife Investment Management LLC increased its position in shares of Vanda Pharmaceuticals by 56.0% in the first quarter. MetLife Investment Management LLC now owns 30,601 shares of the biopharmaceutical company’s stock worth $346,000 after acquiring an additional 10,989 shares in the last quarter. Panagora Asset Management Inc. increased its position in shares of Vanda Pharmaceuticals by 26.1% in the first quarter. Panagora Asset Management Inc. now owns 46,531 shares of the biopharmaceutical company’s stock worth $526,000 after acquiring an additional 9,642 shares in the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS increased its position in shares of Vanda Pharmaceuticals by 14.1% in the first quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 48,029 shares of the biopharmaceutical company’s stock worth $543,000 after acquiring an additional 5,922 shares in the last quarter. Finally, Yousif Capital Management LLC increased its position in shares of Vanda Pharmaceuticals by 2.4% in the first quarter. Yousif Capital Management LLC now owns 50,710 shares of the biopharmaceutical company’s stock worth $574,000 after acquiring an additional 1,180 shares in the last quarter. Institutional investors and hedge funds own 97.92% of the company’s stock.

Analyst Ratings Changes

Separately, StockNews.com upgraded shares of Vanda Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, December 7th.

Get Our Latest Report on VNDA

Vanda Pharmaceuticals Trading Up 11.8 %

Shares of VNDA stock opened at $4.07 on Friday. The company has a market capitalization of $234.15 million, a PE ratio of 19.38 and a beta of 0.68. The firm has a fifty day simple moving average of $3.90 and a 200-day simple moving average of $4.45. Vanda Pharmaceuticals Inc. has a twelve month low of $3.30 and a twelve month high of $8.15.

About Vanda Pharmaceuticals

(Free Report)

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.

Featured Stories

Want to see what other hedge funds are holding VNDA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vanda Pharmaceuticals Inc. (NASDAQ:VNDAFree Report).

Institutional Ownership by Quarter for Vanda Pharmaceuticals (NASDAQ:VNDA)

Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.